Cargando…
Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy
Duchenne muscular dystrophy is an X-linked recessive hereditary monogenic disorder caused by inability to produce dystrophin protein. In most patients, the expression of dystrophin lost due to disrupting mutations in open reading frame. Despite the efforts in a large number of different therapeutic...
Autores principales: | Mollanoori, Hasan, Rahmati, Yazdan, Hassani, Bita, Havasi Mehr, Meysam, Teimourian, Shahram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chongqing Medical University
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099695/ https://www.ncbi.nlm.nih.gov/pubmed/33997161 http://dx.doi.org/10.1016/j.gendis.2019.12.007 |
Ejemplares similares
-
Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2018) -
CRISPR Therapeutics for Duchenne Muscular Dystrophy
por: Erkut, Esra, et al.
Publicado: (2022) -
Multiplex CRISPR/Cas9-Based Genome Editing for Correction of Dystrophin Mutations that Cause Duchenne Muscular Dystrophy
por: Ousterout, David G., et al.
Publicado: (2015) -
Long-term Evaluation of AAV-CRISPR Genome Editing for Duchenne Muscular Dystrophy
por: Nelson, Christopher E., et al.
Publicado: (2019) -
Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy
por: Gee, Peter, et al.
Publicado: (2017)